Nurix therapeutics reports second quarter fiscal 2023 financial results and provides a corporate update

Announced phase 1b expansion cohorts for nx-2127 in non-hodgkin's lymphomas presented data highlighting the potent cellular activity of both nx-5948 and nx-2127 against btki resistance mutations received $20 million licensing payment from gilead for nx-0479, an oral irak4 degrader for the treatment of rheumatoid arthritis and inflammatory diseases maintained strong financial position with cash and marketable securities of $308.6 million as of may 31, 2023 san francisco, july 13, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended may 31, 2023, and provided a corporate update. “the expansion of our nx-2127 clinical trial in non-hodgkin's lymphomas provides an opportunity to identify clinical benefit in a significant patient population,” said arthur t.
NRIX Ratings Summary
NRIX Quant Ranking